Related Experiment Video
Updated: Jan 30, 2026

A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz1, Janice M Mehnert2, Sebastian Bauer3
1Charité Comprehensive Cancer Center, Charitéplatz 1, 10117, Berlin, Germany. Ulrich.Keilholz@charite.de.
Background:
We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial (NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for metastatic disease.
Patients And Methods:
Patients received avelumab (10 mg/kg)-a human anti-PD-L1 antibody. Assessments included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.
Results:
As of December 31, 2016, 51 patients were treated and followed for a median of 24.2 months (range, 16.1-31.5). Most patients had cutaneous (n = 28 [54.9%]) or ocular (n = 16 [31.4%]) melanoma and had received a median of 2 prior lines of therapy (range, 0-4), including ipilimumab (n = 26 [51.0%]). The confirmed ORR was 21.6% (95% CI, 11.3-35.3; complete response, 7.8%; partial response, 13.7%). The median duration of response was not estimable (95% CI, 2.6 months-not estimable). Median PFS and OS were 3.1 months (95% CI, 1.4-6.3) and 17.2 months (95% CI, 6.6-not estimable), respectively. Subgroup analyses suggested meaningful clinical activity (ORR [95% CI]) in patients with non-ocular melanoma (31.4% [16.9-49.3]), PD-L1-positive tumors (42.1% [20.3-66.5]), or prior ipilimumab therapy (30.8% [14.3-51.8]). Thirty-nine patients (76.5%) had a treatment-related adverse event (TRAE), most commonly infusion-related reaction (29.4%), fatigue (17.6%), and chills (11.8%); 4 patients (7.8%) had a grade 3 TRAE. Five patients (9.8%) had an immune-related TRAE (all were grade 1/2). No grade 4 TRAEs or treatment-related deaths were reported.
Conclusion:
Avelumab showed durable responses, promising survival outcomes, and an acceptable safety profile in patients with previously treated metastatic melanoma.
Trial Registration:
ClinicalTrials.gov identifier: NCT01772004 .
Insights
Avelumab demonstrated durable responses and promising survival in patients with metastatic melanoma. This immunotherapy showed an acceptable safety profile, with manageable side effects in the JAVELIN Solid Tumor trial.
Area of Science:
- Oncology
- Immunotherapy
- Clinical Trials
Background:
- Phase 1b data from the JAVELIN Solid Tumor trial (NCT01772004) are presented.
- Focus on patients with unresectable stage IIIC or IV melanoma that progressed after at least one line of therapy for metastatic disease.
Purpose of the Study:
- To evaluate the efficacy and safety of avelumab, a human anti-PD-L1 antibody, in patients with previously treated metastatic melanoma.
- Assess objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety profile.
Main Methods:
- 51 patients received avelumab (10 mg/kg).
- Data collected included ORR, PFS, OS, and safety assessments.
- Follow-up was conducted for a median of 24.2 months.
Main Results:
- Confirmed ORR was 21.6% (95% CI, 11.3-35.3), with a complete response rate of 7.8%.
- Median PFS was 3.1 months (95% CI, 1.4-6.3) and median OS was 17.2 months (95% CI, 6.6-not estimable).
- Meaningful activity observed in subgroups: non-ocular melanoma (ORR 31.4%), PD-L1-positive tumors (ORR 42.1%), and post-ipilimumab therapy (ORR 30.8%).
- 76.5% experienced treatment-related adverse events (TRAEs), most commonly infusion-related reactions and fatigue. Grade 3 TRAEs occurred in 7.8%, and immune-related TRAEs in 9.8% (all grade 1/2). No grade 4 TRAEs or treatment-related deaths.
Conclusions:
- Avelumab demonstrates durable responses and promising survival outcomes in previously treated metastatic melanoma patients.
- The safety profile of avelumab is acceptable, with a low incidence of severe adverse events.
- Avelumab represents a viable treatment option for this patient population.
Related Concept Videos
Phase Diagrams
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Phase Transitions
Clinical Trials: Overview
Trial and Error and Algorithm

